Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety.
This retrospective study sought to compare two modes of administration of antithymocyte globulin (RATG) after renal transplantation.


METHODS
Before 1993, group I patients (n = 93) received fixed doses of RATG (1 mg/kg per day) for 8 consecutive days. Thereafter, RATG was either continued at the same dose for 15 days, in cases of delayed graft function, or was infused every other day at the same dose until serum creatinine level became <150 micromol/L. After 1993, group II patients (n = 66) received RATG at full dose (1 mg/kg per day) during the first 3 days and thereafter the doses were adjusted to target a CD2 T-cell count <50/mm3. Both groups received steroids, azathioprine, and cyclosporine. The mean follow-up after transplantation was 117 +/- 31 months in group I and 93 +/- 19 months in group II.


RESULTS
The RATG cumulative dose and consequently cost were significantly higher among group I than group II patients. Long-term patient and graft survival were similar in both groups. The rate of acute graft-rejection episodes was significantly higher among group I than group II patients. At 7 years posttransplantation, the serum creatinine level and creatinine clearance were similar in the two groups. The rate of cytomegalovirus infection, as well as the cumulative incidence of severe infections and cancers were also similar in both groups. Among the cancers, skin neoplasms represented 30% in group I and 26% in group II (P = ns).


CONCLUSIONS
Adjusting RATG doses according to the CD2 lymphocyte count is safe, and a less expensive than using full doses.
Esposito
L
L
Department of Nephrology, Dialysis and Multiorgan Transplantation, CHU Rangueil Toulouse, France.
Kamar
N
N
Durand
D
D
Rostaing
L
L
D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D005602:France; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology / Q000502:physiology*; D008875:Middle Aged; D011183:Postoperative Complications / Q000145:classification; D012449:Safety; D012878:Skin Neoplasms / Q000453:epidemiology; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003404:Creatinine